Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:APHB NYSEAMERICAN:BPMX OTCMKTS:NGENF NYSEAMERICAN:PFNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHBAmpliphi Biosciences$9.36-5.0%$10.71$0.15▼$1.37$313.27MN/A842,200 shs87,368 shsBPMXBiopharmx$0.00$0.25▼$6.30$111.86MN/A2.15 million shs336,508 shsNGENFNervGen Pharma$5.84$5.84$1.50▼$6.10$360.74MN/A134,507 shsN/APFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/A10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHBAmpliphi Biosciences-4.97%-14.91%-8.06%+15.56%+551.31%BPMXBiopharmx0.00%0.00%0.00%0.00%0.00%NGENFNervGen Pharma0.00%0.00%0.00%0.00%+117.91%PFNXPfenex0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHBAmpliphi Biosciences$9.36-5.0%$10.71$0.15▼$1.37$313.27MN/A842,200 shs87,368 shsBPMXBiopharmx$0.00$0.25▼$6.30$111.86MN/A2.15 million shs336,508 shsNGENFNervGen Pharma$5.84$5.84$1.50▼$6.10$360.74MN/A134,507 shsN/APFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/A10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHBAmpliphi Biosciences-4.97%-14.91%-8.06%+15.56%+551.31%BPMXBiopharmx0.00%0.00%0.00%0.00%0.00%NGENFNervGen Pharma0.00%0.00%0.00%0.00%+117.91%PFNXPfenex0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHBAmpliphi Biosciences 0.00N/AN/AN/ABPMXBiopharmx 0.00N/AN/AN/ANGENFNervGen Pharma 3.00BuyN/AN/APFNXPfenex 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/ABPMXBiopharmxN/AN/AN/AN/AN/AN/ANGENFNervGen Pharma$150K2,404.91N/AN/AN/A∞PFNXPfenexN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AN/ABPMXBiopharmxN/AN/AN/AN/AN/AN/AN/AN/AN/ANGENFNervGen Pharma-$4.07MN/AN/AN/AN/AN/A-73.14%-56.59%5/13/2026 (Estimated)PFNXPfenexN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/ABPMXBiopharmxN/AN/AN/AN/AN/ANGENFNervGen PharmaN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHBAmpliphi BiosciencesN/AN/AN/ABPMXBiopharmxN/AN/AN/ANGENFNervGen Pharma0.0411.2111.21PFNXPfenexN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHBAmpliphi BiosciencesN/ABPMXBiopharmxN/ANGENFNervGen PharmaN/APFNXPfenexN/AInsider OwnershipCompanyInsider OwnershipAPHBAmpliphi BiosciencesN/ABPMXBiopharmxN/ANGENFNervGen PharmaN/APFNXPfenexN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableBPMXBiopharmx1718.28 millionN/ANot OptionableNGENFNervGen Pharma761.77 millionN/ANot OptionablePFNXPfenex7134.30 millionN/ANot OptionableAPHB, PFNX, NGENF, and BPMX HeadlinesRecent News About These CompaniesUCB posts more supportive data from Humira rival bimekizumabNovember 6, 2024 | pharmaphorum.comPNKY Medical Holdings Ltd Class A 300109January 31, 2024 | morningstar.comMLast available seats at PFS West Coast Conference next weekMay 19, 2023 | pharmaphorum.comPLigand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best StocksMay 4, 2023 | news.google.comN150+ Active Companies working to develop 160+ Pipeline ... - Digital JournalApril 12, 2023 | news.google.comNHere's Why You Should Add Ligand (LGND) Stock to Your Portfolio - NasdaqApril 6, 2023 | news.google.comNLENZ Therapeutics Closes $83.5M Series B - San Diego Business JournalMarch 29, 2023 | news.google.comNRanibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital JournalMarch 17, 2023 | news.google.comNGlobal Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswireMarch 15, 2023 | news.google.comNSan Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-TribuneMarch 15, 2023 | news.google.comNOsteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital JournalMarch 13, 2023 | news.google.comNCurrent and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPRMarch 1, 2023 | news.google.comNLigand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield CalifornianFebruary 23, 2023 | news.google.comNLigand Reports Fourth Quarter and Full Year 2022 Financial Results - Business WireFebruary 22, 2023 | news.google.comNBiosimilar Growth Hormones Global Market Report 2023 - Yahoo FinanceFebruary 8, 2023 | news.google.comNBiosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo FinanceFebruary 8, 2023 | news.google.comNOsteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital JournalFebruary 7, 2023 | news.google.comNInjectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.comJanuary 27, 2023 | news.google.comNOsteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital JournalJanuary 27, 2023 | news.google.comNInjectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPRJanuary 6, 2023 | news.google.comNMedia Sentiment Over TimeAPHB, PFNX, NGENF, and BPMX Company DescriptionsAmpliphi Biosciences NYSEAMERICAN:APHB$9.36 -0.49 (-4.97%) As of 05/5/2026AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Biopharmx NYSEAMERICAN:BPMXBioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.NervGen Pharma OTCMKTS:NGENF$5.84 0.00 (0.00%) As of 05/5/2026NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
